Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.

In November 2024, CVS Health appointed Prem Shah as the Group President, responsible for the operational performance across ...

CVS faces pressures from rising medical costs, but promising guidance, stable finances, and low valuations suggest strong ...

CVS Health is a BUY. Undervalued with growth potential, it outshines competitors despite sector challenges. See more on CVS ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $74.12, accompanied by ...

CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Price Action: At the last check on Tuesday, CVS stock was up 9.52% at $69.93 during the premarket session. Read Next: Global Markets Rebound In Relief Rally, Gold Back To $3,000 ...

These ratings reflect expectations for the relative performance of CVS Health ... provide estimates for the future value of CVS Health's stock. This analysis reveals shifts in analysts ...

An in-depth analysis of recent analyst actions ... the company may face hurdles in achieving optimal financial performance. Return on Assets (ROA): CVS Health's ROA stands out, surpassing industry ...

Shares of UnitedHealth Group ended down 22% Thursday after the health-care giant's first-quarter results fell short of ...